Table of Contents
WILMINGTON, Del. —
AstraZeneca has rolled out the Bydureon Pen (exenatide extended-release for injectable suspension, 2 mg), a treatment for type 2 diabetes, available to U.S. pharmacies.
 |
The company said Monday that Bydureon Pen, a prefilled, single-use pen injector, contains the same formulation and dose as the original Bydureon single-dose tray. However, the pen eliminates the need for the patient to transfer the medication between a vial and syringe.
The original Bydureon single-dose tray remains available for current and new patients.
"Bydureon is the first once-weekly treatment option for adults with type 2 diabetes, and Bydureon Pen now offers the same continuous release of exenatide in a prefilled device," stated John Yee, vice president and head of medical affairs for U.S. diabetes at AstraZeneca. "Bydureon has been shown to provide significant HbA1c reduction and, although not a weight-loss medicine, the additional benefit of weight loss."
Bydureon is indicated as an adjunct to diet and exercise to improve blood glucose control in adults with type 2 diabetes.
